Emerging Neurotechnology Startups to Present at 2023 Neurotech Leaders Forum
Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several promising neurotechnology startups and early-stage firms will present at the 2023 Neurotech Leaders Forum in San Francisco, November 6-7. The 23rd annual event—the most established in the industry—will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.
Stakeholders Debate Issues at Neurotech Leaders Forum
About 110 neurotechnology industry professionals, including founders of startup-firms, executives of larger companies, clinicians, university researchers, investors, and government representatives, took part in a series of discussions at the 2023 Neurotech Leaders Forum, produced . Several of the sessions featured lively though respectful debates on critical issues facing the industry, including fu…
2023 in Review
As we bid farewell to another year, it’s worth taking a look at some of the more significant events that took place in the neurotechnology industry in 2023. While the industry has not yet returned to the levels of investment and valuations of 2021, there is certainly more optimism among startups in this space compared to a year ago. Among the neurotech startups and emerging firms who fared well thi…
OAB Vendors Report Progress Toward Commercialization
The bioelectronic medicine market for treating overactive bladder and related disorders is likely to become more congested as new players enter the arena with new targets and new technology. Market leaders Medtronic and Axonics currently own the vast majority of the market for implanted sacral nerve stimulation systems. In recent weeks three new competitors in this space reported progress toward commercial development.
OAB Vendors Report Progress Toward Commercialization
The bioelectronic medicine market for treating overactive bladder and related disorders is likely to become more congested as new players enter the arena with new targets and new technology. Market leaders Medtronic and Axonics currently own the vast majority of the market for implanted sacral nerve stimulation systems. In recent weeks three new competitors in this space reported progress toward commercial development.
Retinal Implant Startups Turn to Optical Technology
The market for visual neuroprosthetics products has taken some interesting turns since our last article on this product category earlier this year [NBR Aug23 p1]. Prominent companies like Second Sight Medical Products and Pixium Vision SA, once pioneers in implantable vision restoration devices, now grapple with financial challenges. In 2022, Second Sight (founded entrepreneur Alfred Mann) merged with Nano Precision Medical, forming Vivani Medical, Inc.
Hearing Us Out
The 23rd annual Neurotech Leaders Forum, which took place in San Francisco earlier this month [see conference report p15], offered an excellent opportunity for neurotech professionals to sound off—and to listen in—on pressing issues confronting the industry. One of the most productive sessions, we think, was devoted to responding to negative publications and negative decisions impacting neuromodulation firms.
Neurotech Executives Sound Off at MedTech Conference
Medical device industry professionals traveled to Anaheim, CA for the 2023 MedTech Conference, produced earlier this month. Neurotechnology firms played an active role in the meeting. One of the unique attributes of this conference was a series of “reverse pitches” in which large strategic medtech firms informed startups of the advantages of partnering with them. Chris Cleary, senior vice president for business development at Medtronic, was one such presenter.
New CMS Rules Will Impact Bioelectronic Medicine Vendors
The U.S. Centers for Medicare & Medicaid Services recently issued draft rules for hospital price transparency, which stand to exert a profound effect on manufacturers of implanted bioelectronic medicine systems. The new rules state that beginning January 1, 2024, CMS will start enforcing the requirement that all U.S.-based hospitals and ambulatory surgical centers publicly list their standard patient charges in a machine-readable file.
Electrogenetics May Offer New Therapy for Type I Diabetes
The interface between technology and medicine has reached a milestone with the development of DART (Direct Current-Actuated Regulatory Technology), an electrogenetic interface that integrates wearable devices with gene-based therapies. This has potential in real-time medical adaptations, specifically in the management of type 1 diabetes—a condition that requires meticulous monitoring and immediate therapeutic interventions.